Freenome is a biotechnology company that focuses on early cancer detection and precision medicine.

Freenome

Guardant Health is a leading precision oncology company specializing in blood-based cancer detection and comprehensive liquid biopsy solutions.

Guardant Health

GRAIL is a healthcare company focused on multi-cancer early detection through blood-based testing and deep sequencing technology.

GRAIL

Exact Sciences is a molecular diagnostics company that focuses on early cancer detection and screening, particularly for colorectal cancer.

Exact Sciences

Personal Genome Diagnostics is a leader in cancer genomics, providing innovative diagnostic technologies for precision oncology.

Personal Genome Diagnostics

Genetron Health is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The company offers diversified solutions covering the full cycle of cancer management, including early screening, diagnostics and monitoring, and biopharma development services.

Genetron Holdings Limited (“Genetron Health” or the “Company”)  is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive product and service portfolio that cover the full-cycle of cancer care from early screening, to diagnosis and treatment recommendations, to continuous monitoring and continuous care.

Genetron Holdings Limited（Genetron Health）

Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.

Genetron Holdings Limited

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

financial_statements

network_onboarding

company_summary

signals

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

news_processing_advanced

peers

news_basic

valuation

customer_profile

NASDAQ:GTH

Genetron Health

Last Close

4.02

28/03 20:00

Market Cap

127.29M

Beta: 0.53

Volume Today

412.60K

Avg: 34.19K

PE Ratio

−2.83

PFCF: −1.52